According to the company, the median number of aura attacks was reduced by 68% (p=0.01) in patients receiving tonabersat when compared with placebo. This result in the primary
The supplemental new drug application (sNDA) submission is supported by a Phase III single-blinded controlled study conducted in Japanese women with no or irregular ovulation, including polycystic ovary
BioCancell is a biopharmaceuticals corporation specializing in the development of patient-oriented, targeted therapy for the treatment of numerous types of cancer. Products under the agreement will be manufactured
The filing is supported by data from three placebo-controlled clinical trials in patients with epilepsy. Previously, Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) and SK Holdings have
Third quarter 2008 net sales from continuing operations were $5.3 billion, an increase of 14%, including a 3% favorable foreign exchange impact, as compared to the corresponding quarter
Since the start of the commercialization of Acomplia, Sanofi-Aventis said that it has been closely collaborating with both the regulatory authorities and healthcare providers to monitor on an
Mr Kogod currently serves as DaVita’s president-west, a role he has occupied since October 2005. Mr Mello, who served as COO since June 2000, will continue with the
Alcon Research Limited (ARL) is an affiliate of Alcon Inc, an eye care company. The alliance combines Origenis’s capabilities in compound design, chemical synthesis, and screening with Alcon’s
The NXL103 Phase II study was a double-blind, multinational, randomized, comparative study that evaluated this oral antibacterial as a treatment for mild to moderate community acquired pneumonia. The
On a pro forma non-GAAP basis, the company recorded net income of $1.13 billion, or $1.04 per share in the third quarter of 2008, compared with third-quarter 2007
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.